Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Li, Fengjiao; Sun, Mingzhu; Guo, Jianlian; Ma, Aihua; Zhao, Bojun

doi:10.1080/02713683.2017.1285943

Cited by 35 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; Li et al. ), statistically significant main outcome measures were reported in 29 of 38 (76%) high‐impact publications and in 4 of 7 (57%) of low‐impact publications (p = 0.43). Correspondence between abstract conclusion and significance of main outcome measure was present in 32 of 38 (84%) high‐impact publications and in 6 of 7 (86%) low‐impact publications (p = 0.96).…”

Section: Resultsmentioning

confidence: 87%

Effect of funding source on reporting bias in studies of intravitreal anti‐vascular endothelial growth factor therapy for retinal vein occlusion

Venincasa

Kuriyan

Sridhar

2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 87%

Effect of funding source on reporting bias in studies of intravitreal anti‐vascular endothelial growth factor therapy for retinal vein occlusion

Venincasa

Kuriyan

Sridhar

2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Since the BEAT-ROP trial, intravitreal anti-VEGF for ROP has gained broad popularity in clinics 2 , 12 , 15 , 17 . The present “standard” dosage of IVC for ROP (0.25 mg in 0.025 mL) stands for a origin of adult doseage of Conbercept treated for conditions such as AMD and retinal vein occlusion (0.5 mg in 0.05 mL) 18 , 19 . The dosage used in the treatment of ROP 12 , 0.25 mg, is half the adult dosage.…”

Section: Discussionmentioning

confidence: 99%

A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Cheng

Meng

Linghu

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15 mg/0.015 mL) of IVC is effective in the treatment of Zone II Stage 2/3 + ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6 ± 2.2 weeks, 39.3 ± 3.0 weeks and 1297.5 ± 429.2 g respectively. Primary effectiveness (react to IVC 0.15 mg alone) was found in 32/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6/38 eyes (15.8%). Follow-up continued until 90 weeks’ postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15 mg IVC is effective for Zone II Stage 2/3 + ROP, and there is no adverse ocular outcomes during the follow-up period.

show abstract

“…It has been reported that conbercept is an effective treatment not only for patients with choroidal neovascularization secondary to punctate inner choroidopathy, 21 neovascular AMD, 22 macular edema secondary to branch retinal vein occlusion, 25 but also for patients with PCV. 23 In this retrospective study, treatment-naive PCV patients treated with conbercept using a “3+PRN” method over 6 months of follow-up visits resulted in a significant improvement in visual acuity and anatomical results.…”

Section: Discussionmentioning

confidence: 99%

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Peng¹,

Zhang²,

Li³

et al. 2018

DDDT

View full text Add to dashboard Cite

IntroductionTo evaluate the functional and morphological outcomes of intravitreal conbercept monotherapy in patients with polypoidal choroidal vasculopathy (PCV).Materials and methodsIn this retrospective, observational case series study, we reviewed medical records of 48 eyes (48 patients) with naive PCV that were treated with a series of 3 monthly intravitreal injections of 0.5 mg of conbercept followed by as-needed injections (3+pro re nata). All patients completed at least 6 months of monthly follow-up. Changes in the best-corrected visual acuity, optical coherence tomography, and indocyanine green angiography were retrospectively evaluated.ResultsAt 6 months, the mean best-corrected visual acuity significantly improved from 0.89±0.35 (20/160 in Snellen equivalent) at baseline to 0.58±0.26 (Snellen equivalent of 20/80; P<0.001), and 60.42% (29/48) of eyes had an improvement of three lines of vision; the mean central retinal thickness significantly decreased from 333.56±171.04 μm at baseline to 187.65±54.46 μm (P<0.001), and 93.75% (45/48) achieved a dry macula. At 3 months, 6 of 32 eyes (18.75%) showed partial regression of branching vascular network, 14 of 32 (43.75%) patients showed complete resolution of polyps. The mean number of injections was 3.4±0.9 through 6 months. No conbercept-related systemic or ocular adverse effects were observed.ConclusionIntravitreal injection of conbercept using “3+pro re nata” regimen significantly improved visual acuity and anatomical outcomes in treatment-naive patients with PCV.

show abstract

Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Abstract: Intravitreal injection of conbercept is shown to be safe and effective for the treatment of ME secondary to BRVO, based on 6-month follow-up data.

Cited by 35 publications

References 10 publications

Effect of funding source on reporting bias in studies of intravitreal anti‐vascular endothelial growth factor therapy for retinal vein occlusion

Effect of funding source on reporting bias in studies of intravitreal anti‐vascular endothelial growth factor therapy for retinal vein occlusion

A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy

Contact Info

Product

Resources

About